MARKET

CVM

CVM

CEL-SCI Corp
AMEX

Real-time Quotes | Nasdaq Last Sale

3.220
+0.220
+7.33%
Closed 19:09 05/25 EDT
OPEN
3.000
PREV CLOSE
3.000
HIGH
3.290
LOW
2.890
VOLUME
790.48K
TURNOVER
--
52 WEEK HIGH
27.28
52 WEEK LOW
2.490
MARKET CAP
139.51M
P/E (TTM)
-3.8008
1D
5D
1M
3M
1Y
5Y
CVM: Second Quarter Fiscal Year 2022 Financial Results
By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT On May 16, 2022, CEL-SCI Corporation (NYSE:CVM) submitted its 2Q:22 Form 10-Q with the SEC. Since our last update in mid-February it has been a light quarter while CEL-SCI has been analyz...
Zacks Small Cap Research · 6d ago
Cel-Sci GAAP EPS of -$0.43 misses by $0.27
Cel-Sci press release (NYSE:CVM): Q1 GAAP EPS of -$0.43 misses by $0.27. As of March 31, 2022, CEL-SCI had $34.3 million in cash and cash equivalents.
Seekingalpha · 05/16 13:00
CEL-SCI Announces Acceptance of Abstracts to ASCO 2022
VIENNA, Va., April 22, 2022--CEL-SCI announces acceptance of abstracts to ASCO 2022.
Business Wire · 04/22 13:21
RBLX, CVM and ATER among mid-day movers
Gainers: Clarus Therapeutics Holdings (CRXT) +87%. Winc (WBEV) +27%. AlloVir (ALVR) +26%. NexImmune (NEXI) +24%. Charah Solutions (CHRA) +22%. Target Hospitality (TH) +20%. Phio Pharmaceuticals (PHIO) +20%. Healthcare Services Group
Seekingalpha · 04/20 16:43
30 Stocks Moving In Wednesday's Mid-Day Session
Gainers Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT) climbed 58.3% to $2.2950 after jumping around 22% on Tuesday.
Benzinga · 04/20 16:13
AXSM, SEV and HUSA among mid-day movers
Gainers: Checkmate Pharmaceuticals (CMPI) +332%. Sono Group (SEV) +66%. ToughBuilt Industries (TBLT) +55%. Petros Pharmaceuticals (PTPI) +40%. Axsome Therapeutics (AXSM) +25%. Cyren (CYRN) +22%. Super Micro Computer (SMCI) +21%. Pulse
Seekingalpha · 04/19 16:28
38 Stocks Moving In Tuesday's Mid-Day Session
Gainers
Benzinga · 04/19 16:16
Checkmate, Petros Pharmaceuticals top healthcare gainers; Lyra, Diffusion lead losers' pack
Gainers: Checkmate Pharmaceuticals (CMPI) +333%. Petros Pharmaceuticals (PTPI) +55%. Axsome Therapeutics (AXSM) +23%. Avinger (AVGR) +11%. Processa Pharmaceuticals (PCSA) +10%. Losers: Lyra Therapeutics (LYRA) -16%. Diffusion Pharmaceuticals (DFFN) -15%. C...
Seekingalpha · 04/19 14:04
More
No Data
Learn about the latest financial forecast of CVM. Analyze the recent business situations of CEL-SCI Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CVM stock price target is 15.00 with a high estimate of 17.00 and a low estimate of 13.00.
High17.00
Average15.00
Low13.00
Current 3.220
EPS
Actual
Estimate
-0.18-0.14-0.09-0.05
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 69
Institutional Holdings: 5.85M
% Owned: 13.50%
Shares Outstanding: 43.33M
TypeInstitutionsShares
Increased
19
2.66M
New
30
493.48K
Decreased
4
177.55K
Sold Out
3
243.82K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.11%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Chief Executive Officer/Director/Treasurer
Geert Kersten
Senior Vice President/Secretary
Patricia Prichep
Senior Vice President
John Cipriano
Senior Vice President
Daniel Zimmerman
Chief Scientific Officer
Eyal Talor
Independent Director
Bruno Baillavoine
Independent Director
Robert Watson
Independent Director
Peter Young
No Data
No Data
About CVM
CEL-SCI Corp is a clinical-stage biotechnology company. The Company is focused on activating the immune system to fight cancer and infectious diseases. The Company is engaged in research and developing the treatments for the cancer and other diseases by using the immune system. The Company’s lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal Phase 3 clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The Company using its Ligand Epitope Antigen Presentation System (LEAPS) technology platform is investigating product candidates include CEL-2000 and CEL-4000. CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis. It is also investigating LEAPS COVID-19 conjugates as a potential treatment of coronavirus (COVID-19) in hospitalized and at-high-risk patients at the University of Georgia’s (UGA) Center.

Webull offers kinds of CEL-SCI Corporation stock information, including AMEX:CVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CVM stock methods without spending real money on the virtual paper trading platform.